Zepbound® and vomiting

Vomiting by dose in the Zepbound® data

The US figures come from SURMOUNT-1 and SURMOUNT-2, the two 72-week placebo-controlled weight trials pooled in Table 1; the 5 mg column holds SURMOUNT-1 only, where nobody had type 2 diabetes ^[1][3]. Canada publishes the same data with patient counts ^[3]. In the EU, where tirzepatide for weight management carries the Mounjaro® name, vomiting is classed as very common in the weight-management and sleep apnoea trials, affecting more than 1 in 10 people, but only common in adult type 2 diabetes trials ^[4]. The sleep apnea trials behind Zepbound®’s second US use report no vomiting percentage of their own; the label says their reactions resembled the weight pool ^[1].

A row that climbs with every dose

Vomiting follows a clearer dose pattern than nausea. Each higher maintenance dose came with a larger share of people reporting it, while nausea levelled off after 5 mg ^[1]. The label gives no reason for the difference. Two cautions keep the numbers in proportion: most people in every group never vomited, and one episode during a dose step counts the same as many ^[1].

The gap with placebo looks large partly because so few people on placebo vomited. Pooling six randomised trials without diabetes, Kommu and colleagues found relative risks on tirzepatide of 5.94 for vomiting, against 3.11 for nausea and 2.92 for diarrhea ^[5]. A manufacturer-funded pooled analysis of SURMOUNT-1 to -4 found that most stomach and bowel events were not serious and clustered in the escalation period ^[6].

From fluid loss to the kidneys

The US label gives kidney injury from fluid loss its own warning, section 5.3. After approval, kidney injury, in some cases needing dialysis, was reported in people taking GLP-1 medicines or Zepbound®, and most had become dehydrated through nausea, vomiting or diarrhea ^[1]. In the weight trials it stayed uncommon, at 0.5% on Zepbound® versus 0.2% on placebo ^[1]. Canada adds that some reported cases involved people with no known kidney disease, and the EU information asks for fluid and electrolyte loss to be avoided, noting that older people may be more susceptible ^[3][4]. A study of US spontaneous reports from 2022 to 2025 counted dehydration among tirzepatide events with more serious outcomes; reports like these show association, not cause ^[10].

The label frames the kidney risk around episodes of fluid loss. A manufacturer-funded post hoc analysis of SURMOUNT-1 and -2 found no unfavourable change in kidney filtration (eGFR) over 72 weeks, while urine albumin fell ^[7]. Section 8.6 says kidney impairment does not alter tirzepatide levels and needs no dose adjustment, but repeats the call for kidney checks when fluid-losing reactions occur ^[1]. Canada does not recommend Zepbound® in end-stage kidney disease because experience there is very limited ^[3]. MedlinePlus lists dehydration, very low blood pressure and some medicines, including anti-inflammatory painkillers (NSAIDs) and certain blood pressure drugs, among causes of sudden kidney damage ^[14], so tell your prescriber what else you are taking if you have been vomiting.

Recognising dehydration early

MedlinePlus describes mild to moderate dehydration as thirst, little or darker yellow urine, headache, muscle cramps, dry cool skin and a sticky mouth, and severe dehydration as very dark or absent urine, dizziness, confusion, a rapid pulse or fast breathing ^[13]. In Canada’s Zepbound® patient leaflet, the dehydration that can end in sudden kidney failure shows itself as pee that is dark yellow and smells strong, intense thirst, or dizziness and light-headedness ^[3].

Blood pressure can fall too. In the US pool, low blood pressure affected 1.6% on Zepbound® against 0.1% on placebo, occurred alongside stomach reactions and dehydration, and was more frequent in people already on blood pressure medicine (2.2% vs 1.2%) ^[1]. Light-headedness after a day of vomiting is worth reporting, especially if you take such medicine.

Why tirzepatide can make you vomit

What the label supports: tirzepatide delays stomach emptying, most after the first dose; most vomiting came during escalation; and the step-up schedule exists to cut the risk of these reactions ^[1]. Canada also records reports of impaired stomach emptying, severe gastroparesis included, and its patient information describes gastroparesis as pain with severe nausea and vomiting, long-lasting belching and bloating ^[3].

What animal work proposes: in mice, rats and musk shrews, activating the GIP receptor, one of tirzepatide’s two targets, blocked vomiting caused by GLP-1 drugs while food intake still fell ^[11]. That has not been measured in people, and in human trials vomiting still rose with the Zepbound® dose ^[1].

General background: MedlinePlus notes that vomiting itself can dehydrate you, and lists stress, strong worry and drugs such as marijuana and opioids among its causes, alongside stomach illness and pregnancy ^[12].

When vomiting points to another problem

Several label warnings feature vomiting as one sign among others. Pancreatitis brings intense, lasting pain in the abdomen that can reach the back ^[1][2]. Gallbladder trouble brings pain high in the abdomen with fever, yellowing or pale stools; Canada adds pain in the right shoulder or between the shoulder blades ^[2][3]. After approval, ileus and bowel obstruction were reported with tirzepatide ^[1], and Canada’s patient leaflet describes ileus as bloating, cramping pain, gas, vomiting, constipation and loss of appetite ^[3]. Injecting more than prescribed is another route: Canada notes that an overdose may show up as stomach symptoms such as nausea ^[3].

What helps while food and drink will not stay down

The Medication Guide’s central advice is to drink fluids to lower the chance of dehydration ^[2]. MedlinePlus’s self-care page for nausea and vomiting adds practical detail ^[12].

• Sit quietly when the queasiness builds, since moving about can make it worse, and stay upright after eating ^[12].
• Take clear liquids in sips; MedlinePlus mentions water, fruit juice, flat soda, and sports drinks to replace minerals lost through vomiting ^[12].
• Choose small, bland, watery foods such as crackers, toast, rice, clear soups or gelatin, and avoid greasy, very salty, spicy or strong-smelling food, caffeine, alcohol and fizzy drinks ^[12].
• Rinse your mouth with water or suck a hard sweet after vomiting ^[12].
• If you vomit soon after taking any of your medicines, tell your provider ^[12]; Zepbound® already slows stomach emptying and can change how tablets are absorbed ^[1].
• Your provider may suggest an anti-sickness medicine; ask before adding one ^[12].

Eating little for days: the nutrition question

Repeated vomiting can mean days of eating very little. Canada’s monograph warns that malnutrition, sometimes severe, has been reported with Zepbound®, including vitamin, mineral and protein deficiency and low body weight, and points to nutritional guidance and, where needed, supplements or support ^[3]. Its patient information lists weight loss, weakness, feeling faint, fatigue, dry skin, irritability and trouble paying attention as possible signs ^[3]. In a post hoc analysis of SURMOUNT-1 to -4 covering 4,726 people, adverse events suggesting malnutrition were rare, for example abnormal weight loss in 0.03% on tirzepatide, although vitamin and mineral levels were not routinely measured ^[9].

Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.